Cargando…
Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer, and is still defined as what it is not. Currently, TNBC is the only type of breast cancer for which there are no approved targeted therapies and maximum tolerated dose chemotherapy with taxanes and anthracycline-containi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740099/ https://www.ncbi.nlm.nih.gov/pubmed/29291168 http://dx.doi.org/10.5306/wjco.v8.i6.437 |